Literature DB >> 2460911

Lipooligosaccharides: the principal glycolipids of the neisserial outer membrane.

J M Griffiss1, H Schneider, R E Mandrell, R Yamasaki, G A Jarvis, J J Kim, B W Gibson, R Hamadeh, M A Apicella.   

Abstract

The outer-membrane glycolipids of bacteria that colonize mucosal surfaces that are not routinely bathed by bile acids often lack the long, hydrophilic and neutral polysaccharides that protect the lipid membranes of enteric bacteria from dispersal. The glycolipid from these organisms is properly termed a lipooligosaccharide. A Neisseria strain makes from two to six lipooligosaccharide molecules that range in Mr from 3,150 to 7,100. Different species of Neisseria commonly make lipooligosaccharides of identical Mr and epitope content. Differences in oligosaccharides account for most of the observed physical heterogeneity. Oligosaccharides consist of (1) partially conserved and highly substituted basal oligosaccharides that branch at heptose residues; (2) a linear segment consisting of (hexose)n residues that determines the length of the oligosaccharide; and (3) terminal sequences that are similar to those of glycosphingolipids. Epitope expression is linked to physical heterogeneity and is modified by the molecular environment of the outer membrane. Serotype epitopes are present only on lipooligosaccharides of a certain Mr. Certain lipooligosaccharides regulate complement activation onto the bacterial surface and, hence, immune lysis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460911     DOI: 10.1093/cid/10.supplement_2.s287

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  31 in total

Review 1.  Gonococcal vaccines.

Authors:  E C Tramont
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

2.  Gonococcal lipooligosaccharide sialylation prevents complement-dependent killing by immune sera.

Authors:  L M Wetzler; K Barry; M S Blake; E C Gotschlich
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

3.  Lipopolysaccharide smooth-rough phase variation in bacteria of the genus Chlamydia.

Authors:  M Lukácová; M Baumann; L Brade; U Mamat; H Brade
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

4.  Lack of serotype-specific antibody response to lipopolysaccharide antigens of Moraxella catarrhalis during lower respiratory tract infection.

Authors:  M Rahman; T Holme; I Jönsson; A Krook
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

5.  Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy.

Authors:  P Brandtzaeg; K Bryn; P Kierulf; R Ovstebø; E Namork; B Aase; E Jantzen
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

6.  Production and characterization of monoclonal antibodies to type 8 lipooligosaccharide of Neisseria meningitidis.

Authors:  X X Gu; C M Tsai; A B Karpas
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

Review 7.  Properdin: New roles in pattern recognition and target clearance.

Authors:  Claudia Kemper; Dennis E Hourcade
Journal:  Mol Immunol       Date:  2008-08-08       Impact factor: 4.407

Review 8.  Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

Authors:  A F Verheul; H Snippe; J T Poolman
Journal:  Microbiol Rev       Date:  1993-03

9.  Enzymatically deacylated Neisseria lipopolysaccharide (LPS) inhibits murine splenocyte mitogenesis induced by LPS.

Authors:  A L Erwin; R E Mandrell; R S Munford
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

10.  Neisseria gonorrhoeae utilizes and enhances the biosynthesis of the asialoglycoprotein receptor expressed on the surface of the hepatic HepG2 cell line.

Authors:  N Porat; M A Apicella; M S Blake
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.